Lost in translation: What is limiting cardiomyoplasty and can tissue engineering help?

David L. Simpson, Samuel C. Dudley

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.

Original languageEnglish (US)
Pages (from-to)210-223
Number of pages14
JournalCurrent Stem Cell Research and Therapy
Volume4
Issue number3
StatePublished - 2009
Externally publishedYes

Fingerprint

Cardiomyoplasty
Tissue Engineering
Induced Pluripotent Stem Cells
Stem Cells
Heart Failure
Adult Stem Cells
Amniotic Fluid
Embryonic Stem Cells
Cardiac Myocytes
Bone Marrow Cells
Myocardium
Skeletal Muscle
Pathology
Wounds and Injuries

Keywords

  • Cell delivery
  • Differentiation
  • Myocardial infarction
  • Paracrine factors
  • Progenitor cell
  • Tissue engineering

ASJC Scopus subject areas

  • Medicine (miscellaneous)

Cite this

Lost in translation : What is limiting cardiomyoplasty and can tissue engineering help? / Simpson, David L.; Dudley, Samuel C.

In: Current Stem Cell Research and Therapy, Vol. 4, No. 3, 2009, p. 210-223.

Research output: Contribution to journalReview article

@article{b0f39d07f088426591f5f4650961aee0,
title = "Lost in translation: What is limiting cardiomyoplasty and can tissue engineering help?",
abstract = "Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.",
keywords = "Cell delivery, Differentiation, Myocardial infarction, Paracrine factors, Progenitor cell, Tissue engineering",
author = "Simpson, {David L.} and Dudley, {Samuel C.}",
year = "2009",
language = "English (US)",
volume = "4",
pages = "210--223",
journal = "Current Stem Cell Research and Therapy",
issn = "1574-888X",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Lost in translation

T2 - What is limiting cardiomyoplasty and can tissue engineering help?

AU - Simpson, David L.

AU - Dudley, Samuel C.

PY - 2009

Y1 - 2009

N2 - Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.

AB - Heart failure accounts for more deaths in the United States than any other detrimental human pathology. Recently, repairing the heart after seemingly irreversible injury leading to heart failure appears to have come within reach. Cellular cardiomyoplasty, transplanting viable cell alternatives into the diseased myocardium, has emerged as a promising possible solution. Translating this approach from the laboratory to the clinic, however, has been met with several challenges, leaving many questions unanswered. This review assesses the state of investigation of several progenitor cell sources, including induced pluripotent stem cells, embryonic stem cells, bone marrow stem cells, adipose-derived adult stem cells, amniotic fluid stem cells, skeletal muscle progenitors, induced pluripotent stem cells and cardiac progenitors. Several current roadblocks to maximum success are discussed. These include understanding the need for cardiomyocyte differentiation, appreciating the role of paracrine factors, and addressing the low engraftment rates using current techniques. Tissue engineering strategies to address these obstacles and to help maximize cellular cardiomyoplasty success are reviewed.

KW - Cell delivery

KW - Differentiation

KW - Myocardial infarction

KW - Paracrine factors

KW - Progenitor cell

KW - Tissue engineering

UR - http://www.scopus.com/inward/record.url?scp=74849092822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74849092822&partnerID=8YFLogxK

M3 - Review article

C2 - 19492979

AN - SCOPUS:74849092822

VL - 4

SP - 210

EP - 223

JO - Current Stem Cell Research and Therapy

JF - Current Stem Cell Research and Therapy

SN - 1574-888X

IS - 3

ER -